HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 60,941 shares, an increase of 557.1% from the September 15th total of 9,274 shares. Based on an average daily volume of 1,348,961 shares, the days-to-cover ratio is presently 0.0 days. Approximately 3.0% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several research firms have commented on HCWB. Wall Street Zen cut shares of HCW Biologics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, HCW Biologics has a consensus rating of “Hold” and an average price target of $30.00.

HCW Biologics Trading Up 4.6%

HCW Biologics stock opened at $1.60 on Friday. HCW Biologics has a 1-year low of $1.50 and a 1-year high of $27.57. The firm has a market capitalization of $3.58 million, a price-to-earnings ratio of -0.06 and a beta of 2.41. The firm has a 50 day simple moving average of $2.45 and a 200 day simple moving average of $4.18.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Friday, August 14th. The company reported ($11.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.98) by ($9.60). HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.14 million.

About HCW Biologics

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.